The Kardigan, the leading heart health company advancing cardiovascular (CV) drug development, has acquired Prolaio, a clinical-fuelled company modernising care and research with real-world patient insights and data. Additionally, Prolaio’s FDA-approved patient monitoring software has prepared the vast, curated CV clinical data sets within the company and established global-leading analytics. The Prolaio’s focus on supporting clinicians to treat heart-based health challenges. With this intelligent business alliance strategy, the Kardigan will achieve access to Prolaio’s industry-popular CV analytics platform and data collection.
The platform and data integration to Kardigan’s Heart Health Company will bolster the company’s recognition and double the advancement, and polish the workflow system more accurately. Prolaio’s spectacular high-density patient data and software into the Kardigan’s pipeline will elevate its research and development and pave the way for progress inflow throughout its streamlined late-stage cardiovascular disease (CVD) assets.
Prolaio’s platform involves a tech-enabled clinical trial enrichment potential that emphasises the superior, accurate data into the insights, especially engineered for CV conditions. This linked data platform allows researchers to utilise clinical study design to mitigate overhead, enhance confidence and accelerate statistical power with excellent data across the study.
Whereas Kardigan’s comprehensive R&D platform elevates an exclusive set of cardiac-based tools. To double its advancement and access, the Prolaio will play a fundamental role. This will allow the deep understanding of the mechanism to flow throughout its capable medicines and the patient’s individual response to treatment. This idea does justice to crucial disease drivers in the treatment responder population to the treatment.
The Co-founder, chair and chief executive officer of Kardigan and co-founder, and co-founder of Prolaio, Tassos Gianakakos, said, “Prolaio and Kardigan both faced challenges in the status quo in cardiology. If we face any shot at any mitigation in cost and time to establish thoughtful new medicines and deliver better healthcare for patients, the biopharma companies have to significantly embrace the AI-based tools and real-world data. This significant integration will reach throughout the R&D.”
The MD, PhD, co-founder and chief medical officer of Kardigan and co-founder of prolaio, Jay Edelberg, also expressed his belief in the meaningful data that is dedicated to transitioning the perspective and idea of therapeutic development. He further discussed about cardiovascular disease beneficial side from this idea that has provided heart information via technology.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
